- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01753765
Study Evaluating the Treatment of Occipital Neuralgia
A Prospective Non-Randomized Unblinded Study Evaluating the Treatment of Occipital Neuralgia With the Cryo-Touch III Device
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Over 100 million patients in the United States suffer from chronic pain. Chronic pain conditions are often debilitating, taking a toll on a patient's physical and mental welfare. Though a variety of pain management techniques currently exist, the most common nonsurgical options provide slow-acting and/or short-term relief. Medication, often in the form of non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, comes with an array of side effects such as nausea and vomiting. Medication also presents the possibility of more serious effects such as increased risk of heart attack and stroke, and tolerance or dependency issues. Surgical strategies tend to be reserved for more severe cases and are limited by the risks and complications typically associated with surgery including bleeding, bruising, scarring, and infection. A nonsurgical, minimally invasive, long-lasting approach to chronic pain management is desirable.
Myoscience, Inc. (Redwood City, CA) has developed a pain management device - the Cryo-Touch III - for a novel, minimally invasive procedure using focused cold therapy to target sensory nerve tissue and offer long-lasting pain relief through cryoanalgesia. The device operates on the well-established cryobiology principle that localized exposure to controlled, moderately low temperature conditions can alter tissue function. The therapy treats nerves via a probe in the form of an assembly of small diameter needles, creating a highly localized, low temperature treatment zone around the probe. This focused cold therapy creates a conduction block that prevents nerve signaling. Prior studies of the Cryo-Touch, Cryo-Touch II, Cryo-Touch III (a.k.a. PCP 1.0) devices have provided preliminary evidence of effectiveness on motor nerves and have been shown to be safe with no serious device-related adverse events.
Though studies have proven efficacious in targeting motor nerves, the device's effect on sensory nerves has yet to be investigated in the clinical setting. The goal of the study described herein is to evaluate the degree and duration of effect of the Cryo-Touch III in reducing chronic pain by targeting sensory nerves.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Napa, California, United States, 94557
- Neurovations
-
-
Idaho
-
Boise, Idaho, United States, 83713
- Injury Care Medical Center
-
-
Kansas
-
Overland Park, Kansas, United States, 66210
- International Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female, 18 years of age and older. Female subjects of childbearing potential must not be pregnant at time of treatment.
- A confirmed diagnosis of occipital neuralgia (unilateral or bilateral) .
- Any medication must be maintained on a stable schedule for at least two weeks prior to treatment. No washout period is allowed.
- Must have an average score for pain of ≥ 4/10 Visual Analog Scale (VAS) over the last 7 days.
- Subject is willing and able to give written informed consent and able to comply with study instructions.
Exclusion Criteria:
- Current diagnosis of fibromyalgia, chronic back pain, or chronic migraines.
- Any injections intended for pain relief or neuromodulation to the upper trunk or head within the last 3 months.
- History of a cerebrovascular accident (CVA), head trauma, stroke, or bone deformity.
- Patient who has severe pain for any reason other than occipital neuralgia.
- Any use of (i.e. oral, topical, inhaled and/or injected) anesthetics or steroids within the last 30 days.
- Any previous surgery in the intended treatment area.
- Currently enrolled in any other investigational drug or device study or participation within the last 30 days.
- Any clotting disorder and/or use of any anticoagulant (e.g., warfarin, clopidogrel, etc.) within seven (7) days prior to administration of the treatment.
- Allergy or intolerance to any preparatory treatment agent or any other substance utilized within the study.
- Any local skin condition at the treatment site that would adversely affect treatment or subject safety.
- Any confounding diagnosis or medical condition that in the investigator's opinion would adversely affect study participation or subject safety.
- Any chronic medication use (prescription, over-the-counter, supplements, etc.) that in the investigator's opinion would adversely affect study participation or subject safety.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Study treatment with Cryo-Touch III device at Day 0.
|
Device: Cryo-Touch III Study treatment at Day 0.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
A Reduction in Either Pain Frequency or Severity Associated With Occipital Neuralgia.
Time Frame: Baseline to Day 7, Baseline to Day 30
|
Improvement of pain due to occipital neuralgia as measured on the Visual Analog Scale (VAS) for pain at Days 7 and 30 as compared to baseline (Day 0).
0= no pain, 10= worst pain imaginable.
Higher scores equal worse outcome.
|
Baseline to Day 7, Baseline to Day 30
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Treatment
Time Frame: Day 30, Day 56
|
Treatment effect was based on Subject response when asked if the Subject had an effect from the treatment.
|
Day 30, Day 56
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MYO-0613
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Occipital Neuralgia
-
Rush University Medical CenterJohns Hopkins UniversityWithdrawnOccipital Neuralgia | Post-Traumatic NeuralgiaUnited States
-
Nantes University HospitalTerminatedOccipital NeuralgiaFrance
-
University of CalgaryCompletedHeadache | Occipital NeuralgiaCanada
-
Johns Hopkins UniversityUnited States Naval Medical Center, San Diego; United States Naval Medical... and other collaboratorsCompletedOccipital NeuralgiaUnited States
-
Allevio Pain Management ClinicNot yet recruitingHeadache | Occipital Neuralgia
-
SPR Therapeutics, Inc.RecruitingCervicogenic Headache | Occipital NeuralgiaUnited States
-
Mayo ClinicCompletedCervicogenic Headache | Occipital NeuralgiaUnited States
-
Aydin Adnan Menderes UniversityRecruitingBlock | Chronic Migraine, Headache | Occipital NeuralgiaTurkey
-
NYU Langone HealthWithdrawn
-
National Institute of Neurological Disorders and...CompletedHealthy | Occipital Cortex | Prefrontal CortexUnited States
Clinical Trials on Device: Cryo-Touch III Study treatment at Day 0.
-
Pacira Pharmaceuticals, IncCompletedUpper Limb SpasticityUnited States
-
Pacira CryoTech, Inc., a wholly owned subsidiary...CompletedEntrapment NeuropathyUnited States
-
Insud PharmaKenya Medical Research Institute; Barcelona Institute for Global Health; European... and other collaboratorsNot yet recruitingSoil-Transmitted HelminthsGhana, Kenya
-
University of Sao PauloCompleted
-
Memorial Sloan Kettering Cancer CenterCompletedRectal CancerUnited States
-
Memorial Sloan Kettering Cancer CenterPfizer; Dana-Farber Cancer Institute; University of Pittsburgh; University of VirginiaCompletedNeurofibromatosis | Meningioma | CNS Cancer | Hemangioblastoma | Intracranial HemangiopericytomaUnited States